These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 16628682)
41. Limited hepatitis B immunoglobulin with potent nucleos(t)ide analogue is a cost-effective prophylaxis against hepatitis B virus after liver transplantation. Singer GA; Zielsdorf S; Fleetwood VA; Alvey N; Cohen E; Eswaran S; Shah N; Chan EY; Hertl M; Fayek SA Transplant Proc; 2015 Mar; 47(2):478-84. PubMed ID: 25769595 [TBL] [Abstract][Full Text] [Related]
42. [Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil]. Xing J; Han T; Liu L; Li Y; Li J; Li Y; Xiao SX Zhonghua Gan Zang Bing Za Zhi; 2011 Nov; 19(11):828-32. PubMed ID: 22433304 [TBL] [Abstract][Full Text] [Related]
43. The feasibility of discontinuing lamivudine in lamivudine-resistant chronic hepatitis B patients on lamivudine and adefovir combination therapy. Chung SM; Byoun YS; Kim HS; Jang ES; Kim JW; Jeong SH Intervirology; 2014; 57(6):337-43. PubMed ID: 25247889 [TBL] [Abstract][Full Text] [Related]
44. Evolving experience of hepatitis B virus prophylaxis in liver transplantation. Honaker MR; Shokouh-Amiri MH; Vera SR; Alloway RR; Grewal HP; Hardinger KL; Kizilisik AT; Bagous T; Trofe J; Stratta RJ; Egidi MF; Gaber AO Transpl Infect Dis; 2002 Sep; 4(3):137-43. PubMed ID: 12421458 [TBL] [Abstract][Full Text] [Related]
45. Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients. Aizawa M; Tsubota A; Fujise K; Tatsuzawa K; Kono M; Hoshina S; Tajiri H J Med Virol; 2011 Jun; 83(6):953-61. PubMed ID: 21503906 [TBL] [Abstract][Full Text] [Related]
46. Comparison of rescue strategies in lamivudine-resistant patients with chronic hepatitis B. Zhao P; Wang C; Huang L; Xu D; Li T Antiviral Res; 2012 Nov; 96(2):100-4. PubMed ID: 22960601 [TBL] [Abstract][Full Text] [Related]
47. Viral persistence after liver transplantation for hepatitis B virus: a cross-sectional study. Freshwater DA; Dudley T; Cane P; Mutimer DJ Transplantation; 2008 Apr; 85(8):1105-11. PubMed ID: 18431229 [TBL] [Abstract][Full Text] [Related]
48. Section 14. Combination of entecavir plus low-dose on-demand hepatitis B immunoglobulin is effective with very low hepatitis B recurrence after liver transplantation. Hu TH; Chen CL; Lin CC; Wang CC; Chiu KW; Yong CC; Liu YW; Eng HL Transplantation; 2014 Apr; 97 Suppl 8():S53-9. PubMed ID: 24849836 [TBL] [Abstract][Full Text] [Related]
49. Favorable outcome of de novo hepatitis B infection after liver transplantation with lamivudine and adefovir therapy. Zhang FK; Zhang Y; Zhang JY; Jia JD; Wang BE Transpl Infect Dis; 2009 Dec; 11(6):549-52. PubMed ID: 19725909 [TBL] [Abstract][Full Text] [Related]
50. Adefovir-based combination therapy with entecavir or lamivudine for patients with entecavir-refractory chronic hepatitis B. Kim SS; Cheong JY; Lee D; Lee MH; Hong SP; Kim SO; Cho SW J Med Virol; 2012 Jan; 84(1):18-25. PubMed ID: 22028068 [TBL] [Abstract][Full Text] [Related]
51. Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation. Ferretti G; Merli M; Ginanni Corradini S; Callejon V; Tanzilli P; Masini A; Ferretti S; Iappelli M; Rossi M; Rivanera D; Lilli D; Mancini C; Attili A; Berloco P Transplant Proc; 2004 Apr; 36(3):535-8. PubMed ID: 15110584 [TBL] [Abstract][Full Text] [Related]
52. Prophylaxis against hepatitis B recurrence posttransplantation using lamivudine and individualized low-dose hepatitis B immunoglobulin. Jiang L; Yan L; Li B; Wen T; Zhao J; Jiang L; Cheng N; Wei Y; Yang J; Xu M; Wang W Am J Transplant; 2010 Aug; 10(8):1861-9. PubMed ID: 20659092 [TBL] [Abstract][Full Text] [Related]
53. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study. Vassiliadis TG; Giouleme O; Koumerkeridis G; Koumaras H; Tziomalos K; Patsiaoura K; Grammatikos N; Mpoumponaris A; Gkisakis D; Theodoropoulos K; Panderi A; Katsinelos P; Eugenidis N J Gastroenterol Hepatol; 2010 Jan; 25(1):54-60. PubMed ID: 19780875 [TBL] [Abstract][Full Text] [Related]
54. Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated decompensated cirrhosis: A meta-analysis. Peng H; Liu J; Yang M; Tong S; Yin W; Tang H; Hu P; Hu H; Ren H J Clin Pharmacol; 2014 Feb; 54(2):189-200. PubMed ID: 24105676 [TBL] [Abstract][Full Text] [Related]
55. Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B. Buti M; Casado MA; Calleja JL; Salmerón J; Aguilar J; Rueda M; Esteban R Aliment Pharmacol Ther; 2006 Feb; 23(3):409-19. PubMed ID: 16423000 [TBL] [Abstract][Full Text] [Related]
56. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. Shim JH; Suh DJ; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288 [TBL] [Abstract][Full Text] [Related]
57. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Zheng S; Chen Y; Liang T; Lu A; Wang W; Shen Y; Zhang M Liver Transpl; 2006 Feb; 12(2):253-8. PubMed ID: 16447195 [TBL] [Abstract][Full Text] [Related]
58. Liver transplantation for hepatitis B virus. Pre-emptive and peri-operative prophylaxis. Mas A Dig Liver Dis; 2009 May; 41 Suppl 2():S191-4. PubMed ID: 19482256 [TBL] [Abstract][Full Text] [Related]
59. [Prevention and management of hepatitis B virus reinfection after liver transplantation]. Ma Y; Tai Q; He XS; Wang GD; Hu AB Zhonghua Wai Ke Za Zhi; 2009 Aug; 47(16):1209-12. PubMed ID: 19781163 [TBL] [Abstract][Full Text] [Related]
60. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Angus PW; McCaughan GW; Gane EJ; Crawford DH; Harley H Liver Transpl; 2000 Jul; 6(4):429-33. PubMed ID: 10915163 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]